ADAGENE INC

Adagene’s insider buy of 2,000 ADS at $3.75 shows leadership’s confidence in its antibody platform and dual‑market strategy, amid a 95% YTD surge.

Ad Gene insider buying shows executives trust the company’s oncology antibody pipeline, underlining growth potential amid value‑based care trends.

Insider purchases at Adagene (ADAG) hint at confidence amid a volatile share price, suggesting a possible rebound as clinical milestones and partnerships unfold.

Adagene insider Gu Chunfang’s latest holdings reveal strong management confidence and strategic alignment with its fast‑track antibody pipeline, signaling potential upside for investors.

Adagene insider activity shows senior execs hold long‑term positions tied to milestone‑based options, balancing dilution risk while aligning leadership incentives with the company’s clinical and commercial goals.